Indomethacin-saccharin cocrystal:: Design, synthesis and preliminary pharmaceutical characterization

被引:326
作者
Basavoju, Srinivas [1 ]
Bostrom, Dan [2 ]
Velaga, Sitaram P. [1 ]
机构
[1] Lulea Univ Technol, Dept Hlth Sci, S-97187 Lulea, Sweden
[2] Umea Univ, Energy Technol & Thermal Proc Chem, S-90187 Umea, Sweden
关键词
crystal engineering; dissolution rate; indomethacin; pharmaceutical cocrystals; poorly soluble drugs;
D O I
10.1007/s11095-007-9394-1
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To design and prepare cocrystals of indomethacin using crystal engineering approaches, with the ultimate objective of improving the physical properties of indomethacin, especially solubility and dissolution rate. Materials and Methods. Various cocrystal formers, including saccharin, were used in endeavours to obtain indomethacin cocrystals by slow evaporation from a series of solvents. The melting point of crystalline phases was determined. The potential cocrystalline phase was characterized by DSC, IR, Raman and PXRD techniques. The indomethacin-saccharin cocrystal (hereafter IND-SAC cocrystal) structure was determined from single crystal X-ray diffraction data. Pharmaceutically relevant properties such as the dissolution rate and dynamic vapour sorption (DVS) of the IND-SAC cocrystal were evaluated. Solid state and liquid-assisted (solvent-drop) cogrinding methods were also applied to indomethacin and saccharin. Results. The IND-SAC cocrystals were obtained from ethyl acetate. Physical characterization showed that the IND-SAC cocrystal is unique vis-a-vis thermal, spectroscopic and X-ray diffraction properties. The cocrystals were obtained in a 1:1 ratio with a carboxylic acid and imide dimer synthons. The dissolution rate of IND-SAC cocrystal system was considerably faster than that of the stable indomethacin gamma-form. DVS studies indicated that the cocrystals gained less than 0.05% in weight at 98%RH. IND-SAC cocrystal was also obtained by solid state and liquid-assisted cogrinding methods. Conclusions. The IND-SAC cocrystal was formed with a unique and interesting carboxylic acid and imide dimer synthons interconnected by weak N-H center dot center dot center dot O hydrogen bonds. The cocrystals were non-hygroscopic and were associated with a significantly faster dissolution rate than indomethacin (gamma-form).
引用
收藏
页码:530 / 541
页数:12
相关论文
共 42 条
[21]  
HORNEDO NR, 2006, MOL PHARM, V3, P362
[22]   Cocrystal formation during cogrinding and storage is mediated by amorphous phase [J].
Jayasankar, Adivaraha ;
Somwangthanaroj, Anongnat ;
Shao, Zezhi J. ;
Rodriguez-Hornedo, Nair .
PHARMACEUTICAL RESEARCH, 2006, 23 (10) :2381-2392
[23]   THE SO2 STRETCHING VIBRATIONS IN SOME METAL SACCHARINATES - SPECTRA-STRUCTURE CORRELATIONS [J].
JOVANOVSKI, G ;
TANCEVA, S ;
SOPTRAJANOV, B .
SPECTROSCOPY LETTERS, 1995, 28 (07) :1095-1109
[24]  
Jovanovski G, 2000, CROAT CHEM ACTA, V73, P843
[25]  
Kaushal Aditya Mohan, 2004, Crit Rev Ther Drug Carrier Syst, V21, P133, DOI 10.1615/CritRevTherDrugCarrierSyst.v21.i3.10
[26]   Saccharin: a combined experimental and computational thermochemical investigation of a sweetener and sulfonamide [J].
Matos, MAR ;
Miranda, MS ;
Morais, VMF ;
Liebman, JF .
MOLECULAR PHYSICS, 2005, 103 (2-3) :221-228
[27]   Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinylacetate) in relation to indomethacin crystallization [J].
Matsumoto, T ;
Zografi, G .
PHARMACEUTICAL RESEARCH, 1999, 16 (11) :1722-1728
[28]   Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API [J].
McNamara, Daniel P. ;
Childs, Scott L. ;
Giordano, Jennifer ;
Iarriccio, Anthony ;
Cassidy, James ;
Shet, Manjunath S. ;
Mannion, Richard ;
O'Donnell, Ed ;
Park, Aeri .
PHARMACEUTICAL RESEARCH, 2006, 23 (08) :1888-1897
[29]   Phase solubility diagrams of cocrystals are explained by solubility product and solution complexation [J].
Nehm, SJ ;
Rodríguez-Spong, B ;
Rodríguez-Hornedo, N .
CRYSTAL GROWTH & DESIGN, 2006, 6 (02) :592-600
[30]  
O'Brien M., 1984, ANAL PROFILES DRUG S, V13, P211, DOI 10.1016/S0099-5428(08)60192-6